Lord, Abbett & Co
BEAM icon

Lord, Abbett & Co’s Beam Therapeutics BEAM Stock Holding History

Lord, Abbett & Co’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-80,294
Closed -$3.11M – 562
2022
Q2 		$3.11M Buy
80,294
+15,725
+24% +$625K 0.01% 526
2022
Q1 		$3.7M Buy
64,569
+258
+0.4% +$16.9K 0.01% 572
2021
Q4 		$5.13M Sell
64,311
-771
-1% -$66K 0.01% 551
2021
Q3 		$5.66M Sell
65,082
-1,060
-2% -$106K 0.01% 584
2021
Q2 		$8.51M Sell
66,142
-6,303
-9% -$502K 0.02% 555
2021
Q1 		$5.8M Sell
72,445
-98,027
-58% -$9.33M 0.01% 582
2020
Q4 		$13.9M Sell
170,472
-5,202
-3% -$256K 0.04% 476
2020
Q3 		$4.33M Buy
+175,674
New +$4.36M 0.01% 578

Other funds holding BEAM

ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Lord, Abbett & Co's BEAM Position: Q3 2022 in Review

Lord, Abbett & Co sold out of Beam Therapeutics (BEAM) in Q3 2022, closing a stake of 80,294 shares — an estimated $3.11M sold.

Lord, Abbett & Co first reported a position in BEAM in Q3 2020 and held it in 8 quarters. The position peaked at $13.9M in Q4 2020. 224 funds tracked by Wall St. Rank hold BEAM as of Q3 2022.

  • Lord, Abbett & Co reported no remaining Beam Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Lord, Abbett & Co sold 80,294 Beam Therapeutics shares in Q3 2022, an estimated $3.11M.
  • Lord, Abbett & Co first reported a position in Beam Therapeutics in Q3 2020 and held it in 8 quarters.
  • Lord, Abbett & Co's Beam Therapeutics position peaked at $13.9M in Q4 2020.
  • 224 funds tracked by Wall St. Rank held Beam Therapeutics as of Q3 2022.

Based on Lord, Abbett & Co's 13F filing for Q3 2022, filed 14 Nov 2022.